Bulk Pharmaceutical API Sources for NEOSCAN

Bulk Pharmaceutical API Sources for NEOSCAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Alfa Chemistry		41183-64-6
J&H Chemical Co.,ltd		JH293099
RR Scientific		R213707
Alfa Chemistry		ACM41183646
EvitaChem		evt-1556492

Bulk Active Pharmaceutical Ingredient (API) Sources for NEOSCAN

Last updated: July 30, 2025

---

Introduction

Neoscan is a diagnostic imaging agent primarily used in nuclear medicine to visualize pulmonary perfusion. With its growing demand in clinical diagnostics, the sourcing of its active pharmaceutical ingredient (API) is crucial for pharmaceutical manufacturers, distributors, and healthcare providers. Ensuring reliable, high-quality API sources guarantees product efficacy, regulatory compliance, and supply chain stability. This report explores the global landscape of bulk API suppliers for NEOSCAN, emphasizing sourcing strategies, key suppliers, and industry insights to guide procurement decisions.

---

Overview of NEOSCAN and Its API

Neoscan, a registered trademark for technetium-99m (Tc-99m) labeled macroaggregated albumin (MAA), relies on the production of MAA particles labeled with Tc-99m, which is derived from molybdenum-99 (Mo-99). The API involved in NEOSCAN production encompasses:

• Macroscopic Albumin Particles: The macroaggregated albumin, a biologic agent that forms microparticles
• Technetium-99m (Tc-99m): The radioactive isotope, generated from Mo-99 generators
• Molybdenum-99 (Mo-99): The parent isotope, critical for technetium-99m generation

The core API source in NEOSCAN's manufacturing process primarily involves Macroparticles of Albumin and Tc-99m radiolabeling kits, supplied by various manufacturers globally.

---

Key API Sources for NEOSCAN

1. Technetium-99m (Tc-99m) Generators

Tc-99m is produced via fission of highly enriched uranium (HEU) or low-enriched uranium (LEU) targets, with supply primarily from specialized isotope producers:

• PerkinElmer (Canada)
  A leading supplier of Mo-99/Tc-99m generators, PerkinElmer provides high-quality, reliable Tc-99m generators globally, with products that meet stringent pharmacopeial standards. They utilize LEU-based production, aligning with non-proliferation initiatives.

• GE Healthcare (USA/Europe)
  GE supplies a broad spectrum of Tc-99m generators, notably the TECHNECATE line, with consistent production and regulatory compliance. Their generators are optimized for high elution efficiency and minimal breakthrough.

• Curium (France)
  Operating one of Europe's primary Mo-99 production facilities using LEU, Curium offers generator services with stable supply channels.

• Iris Pharma (France)
  Specializes in Mo-99/ Tc-99m generators utilizing LEU, supporting sustainable and secure isotope sourcing.

2. Molybdenum-99 (Mo-99)

While Mo-99 is a precursor to Tc-99m, its supply chain stability directly impacts NEOSCAN availability:

• Canadian Nuclear Laboratories (CNL)
  As a major global Mo-99 producer from their NRU reactor, CNL supplies high-purity Mo-99, primarily for generator manufacturing.

• NTP Radioisotopes (South Africa)
  Supplies Mo-99 derived from LEU targets, contributing to diversified, secure supply options.

• Kemmed (Russia)
  A significant supplier of Mo-99, focusing on expanding LEU-based production.

3. Macroparticles of Albumin (MAA)

The biological API component in NEOSCAN, MAA, is synthesized by specialized pharmaceutical firms:

• Covidien (Medtronic, USA)
  The original producer of Technescan Macroaggregated Albumin, Covidien’s MAA kits are widely used in nuclear medicine applications, including NEOSCAN. Their products are characterized by high particle uniformity and purity.

• Bracco Imaging (Italy)
  Manufactures biodegradable MAA kits with proven reliability, adhering to international pharmacopeia standards.

• GE Healthcare (UK/USA)
  Offers MAA kits with consistent particle size, optimized for pulmonary perfusion imaging.

• Atom® Medical (Japan)
  Provides MAA kits with high labeling efficiency, catering to Asian markets but globally accessible.

• Brand-specific imported MAA kits
  Several regional manufacturers supply compendial-grade MAA for local markets, emphasizing quality control and regulatory compliance.

---

Industry Trends & Considerations in API Sourcing

Supply Chain Security

The reliance on Mo-99, historically produced from HEU targets, has faced challenges due to reactor shutdowns and geopolitical factors. The industry has shifted toward LEU-based production to enhance non-proliferation compliance. Diversification across multiple suppliers, particularly with regional production capabilities, is vital for uninterrupted NEOSCAN supply.

Quality & Compliance

API suppliers must adhere to stringent pharmacopeial standards, including USP, EP, or JP, ensuring particle size distribution, radiochemical purity, sterility, and biocompatibility. Suppliers should possess Good Manufacturing Practice (GMP) certification and thorough validation protocols.

Technological Innovations

Advancements in generator design, such as solid-state technology and improved targeting systems, influence API specifications, including Mo-99 purity and MAA particle uniformity, impacting final NEOSCAN product quality.

---

Conclusion

The successful sourcing of NEOSCAN's API hinges on a diversified, high-quality supply chain encompassing Mo-99 and Tc-99m generators, along with macroaggregated albumin. Key global suppliers include PerkinElmer, GE Healthcare, Curium, and Covidien, supported by regional manufacturers adapting to evolving regulatory landscapes. Strategic procurement should emphasize supplier reliability, regulatory compliance, and technological innovation to ensure consistent, safe, and effective NEOSCAN production.

---

Key Takeaways

• Diverse Supply Sources: Rely on multiple reputable suppliers for Tc-99m generators and MAA kits to mitigate supply chain risks.
• Embrace LEU-based Mo-99 Production: Prioritize suppliers leveraging low-enriched uranium to align with non-proliferation standards.
• Ensure Quality Compliance: Verify suppliers’ adherence to internationally recognized GMP standards and pharmacopeial specifications.
• Monitor Industry Trends: Stay informed on technological developments, reactor shutdowns, and regulatory changes affecting isotope and API availability.
• Strategic Stockpiling: Consider inventory buffers for high-demand periods or geopolitical disruptions.

---

FAQs

1. How does the shift from HEU to LEU impact NEOSCAN API sourcing?
Transitioning to LEU-based Mo-99 reduces proliferation concerns and aligns with international regulations. It can affect isotopic yields and radiochemical purity, requiring suppliers to optimize manufacturing. For buyers, this shift may influence procurement timelines and costs but ultimately enhances supply security.

2. Are there regional differences in API suppliers for NEOSCAN?
Yes. Western countries predominantly source Tc-99m generators from PerkinElmer, GE Healthcare, or Covidien, whereas Asian markets may rely on local manufacturers like Atom Medical. Regional geopolitical factors and regulatory environments influence supplier options.

3. What quality standards must MAA and Tc-99m generator suppliers meet?
Suppliers should comply with GMP, ISO standards, and pharmacopeial specifications (USP, EP, JP) covering sterility, endotoxin levels, radiochemical purity, and particle size distribution.

4. How do supply disruptions of Mo-99 affect NEOSCAN production?
Mo-99 shortages lead to reduced Tc-99m availability, directly impacting NEOSCAN availability. Diversified sourcing, using regional reactors, and developing alternative production methods mitigate this risk.

5. What role do emerging technologies play in API sourcing for NEOSCAN?
Innovations in generator design, isotope production (such as cyclotron-based Tc-99m), and improved macroaggregate synthesis are expanding API options, enhancing reliability, and potentially reducing costs.

---

References

[1] International Atomic Energy Agency (IAEA). "Status and Trends in Molybdenum-99 Production," 2022.
[2] US Food and Drug Administration (FDA). "Guidance for Industry: Current Good Manufacturing Practice (CGMP) Regulations," 2021.
[3] PerkinElmer. "Mo-99 / Tc-99m Generators – Product Information," 2022.
[4] GE Healthcare. "Technescan Macroaggregated Albumin (MAA)," 2023.
[5] Covidien (Medtronic). "Technescan Macroaggregated Albumin API," 2022.